Can the promotion of post-exposure prophylaxis following sexual exposure to HIV (PEPSE) cause harm?

Sexually Transmitted Infections

Volumn 81, Issue 3, 2005, Pages 190-191

  Richens, John ^a   Edwards, S G ^a   Sadiq, S T ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EDITORIAL; HEALTH CARE POLICY; HOMOSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; PROPHYLAXIS; RISK REDUCTION; SAFE SEX; SEXUAL TRANSMISSION; SEXUALLY TRANSMITTED DISEASE; UNITED KINGDOM; UNITED STATES; VIRUS TRANSMISSION;

HEALTH PROMOTION; HIV INFECTIONS; HOMOSEXUALITY, MALE; HUMANS; MALE; PRACTICE GUIDELINES; UNSAFE SEX;

EID: 20644464355     PISSN: 13684973     EISSN: None     Source Type: Journal    
DOI: 10.1136/sti.2005.014886     Document Type: Editorial

References (15)

1. Elford J, Bolding G, Davis M, et al. Trends in sexual behaviour among London homosexual men 1998-2003: implications for HIV prevention and sexual health promotion. Sex Transm Infect 2004;80:451-4.
2. Sadiq ST, Taylor S, Kaye S, et al. The effects of antiretroviral therapy on HIV-1 RNA loads in seminal plasma in HIV-positive patients with and without urethritis. AIDS 2002;16:219-25.
3. Elford J. HIV treatment optimism and high-risk sexual behaviour among gay men: the attributable population risk. AIDS 2004;18:2216-7.
4. Clinical Effectiveness Group (British Association of Sexual Health, HIV). United Kingdom Guideline for the use of post-exposure prophylaxis for HIV following sexual exposure, www.bashh.org/ guidelines/draft_04/ pepse%5B1%5D_010404.doc, accessed 21 Jan, 2005.
5. CDC. Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States. MMWR 2005;54(RR02):1-20.
6. Cardo DM, Culver DH, Ciesielski CA, et al. A case-control study of HIV seroconversion in health care workers after percutaneous exposure to HIV-infected blood: clinical and public health implications. N Engl J Med 1997;337:1485.
7. Wade NA, Birkhead GC, Warren BL, et al. Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus. N Engl J Med 1998;339:1409-14.
8. Otten RA, Smith DK, Adams DR, et al. Efficacy of postexposure prophylaxis after intravaginal exposure of pig-tailed macaques to a human-derived retrovirus (human immunodeficiency virus type 2). J Virol 2000;74:9771-5.
9. Tsai CC, Emau P, Follis KE, et al. Effectiveness of post-inoculation PMPA treatment for prevention of persistent SIV infection depends critically on timing of initiation and duration of treatment. J Virol 1998;72:4265-73.
10. Schecter M, Lago RF, Mendelson AB, et al. Behavioural impact, acceptability and HIV incidence among homosexual men with access to postexposure chemoprophylaxis for HIV. J Acquir Immun Defic Syndr 2004;35:519-25.
11. Martin JN, Roland ME, Neilands TB, et al. Use of postexposure prophylaxis against HIV infection following sexual exposure does not lead to increases in high-risk behavior. AIDS 2004;18:787-92.
12. Waldo CR, Stall RD, Coastes TJ. Is offering post-exposure prevention for sexual exposures to HIV related to sexual risk behaviour in gay men? AIDS 2000;14:1035-9.
13. Pinkerton SD, Martin JN, Roland ME, et al. Cost-effectiveness of HIV postexposure prophylaxis following sexual or injection drug exposure in 96 metropolitan areas in the United States. AIDS 2004;18:2065-73.
14. Wilde GJS. Target risk. Dealing with the danger of death, disease and damage in everyday decisions, PDE Publications, 1994.
15. Richens J, Imrie J, Copas A. Condoms and seat belts: the parallels and the lessons. Lancet 2000;355:400-3.